<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DOXEPIN HYDROCHLORIDE</span><br/>(dox'e-pin)<br/><span class="topboxtradename">Adapin, </span><span class="topboxtradename">Sinequan, </span><span class="topboxtradename">Triadapin <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Zonalon<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">psychotherapeutic</span>; <span class="classification">tricyclic antidepressant</span><br/><b>Prototype: </b>Imipramine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg capsules; 10 mg/mL oral concentrate</p>
<h1><a name="action">Actions</a></h1>
<p>Dibenzoxepin is a tricyclic antidepressant (TCA). Reportedly one of the most sedating of the TCAs. Inhibits serotonin reuptake
         from the synaptic gap; also inhibits norepinephrine reuptake to a moderate degree.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Restores the level of these neurotransmitters (serotonin and norepinephrine) as the proposed mechanism of antidepressant action.</p>
<h1><a name="uses">Uses</a></h1>
<p>Psychoneurotic anxiety or depressive reactions; mixed symptoms of anxiety and depression; anxiety or depression associated
         with alcoholism; organic disease; psychotic depressive disorders; topical for treatment of pruritus.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Peptic ulcer disease, neuralgia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Prior sensitivity to any TCA; during acute recovery phase following MI; glaucoma; prostatic hypertrophy; tendency for urinary
         retention; concurrent use of MAO inhibitors. Safe use during pregnancy (category C), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Patients receiving Electroconvulsive Therapy, patients with suicidal tendency; renal, cardiovascular or hepatic dysfunction.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Antidepressant</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 30150 mg/d h.s. or in divided doses, may gradually increase to 300 mg/d (use lower doses in older adult patients)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 1025 mg h.s., may gradually increase to 75 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 13 mg/kg/d in single or divided doses<br/><br/><span class="indicationtitle">Pruritus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> apply a thin film q.i.d. with at least 34 h between applications, may use up to 8 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give oral concentrate diluted with approximately 120 mL water, milk, or fruit juice.</li>
<li>Empty capsule and swallow contents with fluid or mix with food as necessary if it cannot be swallowed whole.</li>
<li>Inform physician if daytime sedation is pronounced. Entire daily dose (up to 150 mg) may be prescribed for bedtime administration.</li>
</ul><span class="adminroutetype">Topical</span><br/><ul>
<li>Apply a thin film to affected areas; allow 34 h between applications.</li>
<li>Store all forms at 15°30° C (59°86° F) in tightly closed, light-resistant container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> All:</span> Anticholinergic. <span class="typehead">CNS:</span> <span class="speceff-common">Drowsiness,</span> dizziness, weakness, fatigue, headache, hypomania, confusion, tremors, paresthesias. <span class="typehead">CV:</span> <span class="speceff-common">Orthostatic hypotension,</span> palpitation, hypertension, tachycardia, ECG changes. <span class="typehead">Special Senses:</span> Mydriasis, blurred vision, photophobia. <span class="typehead">GI:</span> <span class="speceff-common">Dry-mouth,</span> sour or metallic taste, epigastric distress, constipation. <span class="typehead">Urogenital:</span> Urinary retention, delayed micturition, urinary frequency. <span class="typehead">Other:</span> Increased perspiration, tinnitus, weight gain, photosensitivity reaction, skin rash, agranulocytosis, <span class="speceff-common">burning or stinging at application site,</span> edema. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May decrease some antihypertensive response to <span class="classification">antihypertensives</span>; <span class="classification">cns depressants</span>, <b>alcohol,</b> <span class="classification">hypnotics</span>, <span class="classification">barbiturates</span>, <span class="classification">sedatives</span> potentiate CNS depression; may increase hypoprothrombinemic effect of <span class="classification">oral anticoagulants</span>; <b>ethchlorvynol</b> may cause transient delirium; <b>levodopa,</b> <span class="classification">sympathomimetics</span> (e.g., <b>epinephrine,</b> <b>norepinephrine</b>) introduce possibility of sympathetic hyperactivity with hypertension and hyperpyrexia; <span class="classification">mao inhibitors</span> introduce possibility of severe reactions, toxic psychosis, cardiovascular instability; <b>methylphenidate</b> increases plasma TCA levels; <span class="classification">thyroid agents</span> may increase possibility of arrhythmias; <b>cimetidine</b> may increase plasma TCA levels. <span class="typehead">Herbal:</span> <b>Ginkgo</b> may decrease seizure threshold; <b>St. John's wort</b> may cause <b>serotonin</b> syndrome. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI sites through intact skin. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 68 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor use of other CNS depressants, including alcohol. Danger of overdosage or suicide attempt is increased when patient
            uses excessive amounts of alcohol.
         </li>
<li>Be alert to changes in voiding and evaluate patient for constipation and abdominal distention; drug has moderate to strong
            anticholinergic effects.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Maintain established dosage regimen and avoid change of intervals, doubling, reducing, or skipping doses.</li>
<li>Consult physician about safe amount of alcohol, if any, that can be taken. The actions of both alcohol and doxepin are potentiated
            when used together and for up to 2 wk after doxepin is discontinued.
         </li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>